Latent Tuberculosis Clinical Trial
Official title:
Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection
This is a Phase I, open-label, dose-escalation study with three study groups. This study will be conducted in 25 HIV negative subjects, 17 of whom will have Latent Tuberculosis Infection (LTBI) and 8 of whom will not have LTBI at study enrollment. The investigational product is AERAS-456 at a dose of 15 ug of H56 antigen with IC31 500 nmol KLK (15/500), and a dose of 50 ug of H56 antigen with IC31 500 nmol KLK (50/500). The vaccine is administered by intramuscular injection.
This is a Phase I, open-label, dose-escalation study with three study groups. This study will
be conducted in 25 HIV negative subjects, 17 of whom will have Latent Tuberculosis Infection
(LTBI) and 8 of whom will not have LTBI at study enrollment. The investigational product is
H56:IC31 (AERAS-456) at a dose of 15 ug of H56 antigen with IC31 500 nmol KLK (15/500), and a
dose of 50 ug of H56 antigen with IC31 500 nmol KLK (50/500). The vaccine is administered by
intramuscular (IM) injection.
Subjects will be assigned to a study group based on LTBI status at enrollment and time of
completion of screening. Subjects without LTBI will be assigned to Group 1. Subjects with
LTBI will be sequentially assigned to Groups 2 and 3 based on the order in which they
complete screening. All subjects will receive a first dose of study vaccine on Study Day 0, a
second dose of study vaccine on Study Day 56, and a third dose of study vaccine on Study Day
112. Enrollment of subjects into Group 2 will begin only after a review of safety data from
the 14-day period after initial vaccination of all subjects in Group 1. Likewise, enrollment
of subjects into Group 3 will begin only after the corresponding review of safety data from
Group 2.
The total duration of study follow-up for all subjects is 210 days. Study groups 1-2 will
enroll 8 subjects each and study group 3 will enroll 9 subjects. This study is planned at a
single clinical site in South Africa. The sizes specified for each study group were selected
because they are judged to be adequate for preliminary safety and immunogenicity evaluations
for a Phase I study rather than for statistical reasons.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05073926 -
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
|
||
| Not yet recruiting |
NCT04428294 -
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
|
Phase 4 | |
| Completed |
NCT02276755 -
Vitamin D Supplementation in TB Prevention
|
Phase 3 | |
| Withdrawn |
NCT03498534 -
Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
|
Phase 4 | |
| Active, not recruiting |
NCT03988933 -
2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
|
Phase 2 | |
| Recruiting |
NCT06022146 -
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
|
Phase 3 | |
| Active, not recruiting |
NCT04188041 -
Improving Rhode Island's Tuberculosis Preventive Services in Primary Care
|
N/A | |
| Recruiting |
NCT03730181 -
Tuberculosis Clinical Trials Consortium Study 35
|
Phase 1/Phase 2 | |
| Completed |
NCT00257907 -
Immune Response to Mycobacterium Tuberculosis Infection
|
||
| Recruiting |
NCT05756582 -
Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
|
||
| Active, not recruiting |
NCT04557176 -
TB Screening Improves Preventive Therapy Uptake
|
N/A | |
| Completed |
NCT02119130 -
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa
|
N/A | |
| Not yet recruiting |
NCT06281834 -
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
|
Phase 1 | |
| Not yet recruiting |
NCT02512484 -
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
|
N/A | |
| Completed |
NCT00763295 -
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
|
N/A | |
| Completed |
NCT01850043 -
The Epidemiology of TST Change in Korea
|
N/A | |
| Completed |
NCT02090374 -
Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
|
N/A | |
| Completed |
NCT02073669 -
Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults
|
N/A | |
| Completed |
NCT02880982 -
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
|
Phase 3 | |
| Withdrawn |
NCT03783728 -
Video Based Directly Observed Therapy for Latent TB
|